Methods and compositions related to Hsp90 inhibitors and breast cancer
Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.
1. A method of treating breast cancer, comprising administering to a patient determined to have breast cancer cells that are chemo-resistant or not chemo-sensitive an effective amount of a combination of an Hsp90 inhibitor followed by or at the same time with at least one apoptosis-inducing agent, wherein the patient has been determined to have breast cancer cells that are glucocorticoid receptor positive (GR + ) and androgen receptor positive (AR + ).
2. The method of claim 1 , wherein the patient has been determined to have cancer cells that do not express detectable levels of any of estrogen receptor, progesterone receptor, and Her2/neu.
3. The method of claim 1 , wherein at least one apoptosis inducing agent is radiation, a chemotherapeutic, or an immunotherapy.
4. The method of claim 1 , wherein the patient was previously administered a first apoptosis inducing agent more than two weeks prior to the Hsp90 inhibitor.
5. The method of claim 4 , wherein the patient has cancer cells that were determined to be resistant to apoptosis at the time of administration of the first apoptosis inducing agent.
6. The method of claim 1 , wherein the patient is determined to have cancer cells that are resistant to apoptosis.
7. The method of claim 1 , wherein the apoptosis inducing agent is administered within 1 week of the Hsp90 inhibitor.
8. The method of claim 1 , wherein the Hsp90 inhibitor is administered up to three days prior to administering the apoptosis inducing agent.
9. The method of claim 1 , wherein the breast cancer is an unresectable breast cancer.
10. The method of claim 1 , wherein the determination of GR + status comprises determining the expression of one or more GR-responsive genes selected from the group consisting of MCL1, SAP30, SMARCA2, PTGDS, TNFRSF9, SFN, LAPTM5, GPSM2, SORT1, DPT, NRP1, ACSL5, BIRC3, NNMT, IGFBP6, PLXNC1, SLC46A3, C14orf139, PIAS1, IDH2, SERPINF1, ERBB2, PECAM1, LBH, ST3GAL5, IL1R1, BIN1, WIPF1, TFPI, FN1, FAM134A, NRIP1, RAC2, SPP1, PHF15, BTN3A2, SESN1, MAP3K5, DPYSL2, SEMA4D, STOM, MAOA, ANGPTL4 (Angiopoietin-like 4), BCL6 (B-cell CLL/lymphoma 6), CALCR (CALCITONIN RECEPTOR), CEBPB (CCAAT/enhancer binding protein (C/EBP), beta), DDIT4 (DNA-damage-inducible transcript 4), DUSP1 (Dual specificity phosphatase 1), EDN1 (Endothelin 1, ERRFI1 (ERBB receptor feedback inhibitor 1), FKBP5 (FK506 binding protein 5), GLUL (Glutamate-ammonia ligase), IL6R (Interleukin 6 receptor), KLF13 (Kruppel-like factor 13), KLF9 (Kruppel-like factor 9), LOX (Lysyl oxidase), MT1E (Metallothionein 1E), MT2A (Metallothionein 2A), NFKBIA (Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor), alpha, PER1 (Period homolog 1 ( Drosophila )), RHOB (Ras homolog gene family, member B), SESN1 (Sestrin 1), SGK1 (Serum/glucocorticoid regulated kinase 1), SLC19A2 (Solute carrier family 19 (thiamine transporter), member 2), SLC22A5 (Solute carrier family 22 (organic cation/carnitine transporter), member 5), TNFAIP3 (Tumor necrosis factor, alpha-induced protein 3), TSC22D3 (TSC22 domain family, member 3), USP2 (Ubiquitin specific peptidase 2), XDH (Xanthine dehydrogenase), or ZFP36 (Zinc finger protein 36, C3H type, homolog (mouse)).
11. The method of claim 1 , wherein the determination of GR + status comprises measuring the expression of one or more GR-responsive genes or GR in one or more circulating tumor cells.
12. The method of claim 1 further comprising:
a) administering radiation or a chemotherapeutic to the patient after the patient has been administered an effective amount of a combination of an Hsp90 inhibitor followed by or at the same time with at least one apoptosis-inducing agent.
13. The method of claim 1 , wherein the patient has been determined to have breast cancer cells that do not express detectable levels of any of estrogen receptor, progesterone receptor, and Her2/neu.
14. The method of claim 1 , wherein the patient was previously administered a first chemotherapeutic more than two weeks prior to the combination of anti-cancer compounds.